Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer

This publication has 18 references indexed in Scilit:

• Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
  Molecular Cancer Therapeutics, 2010
• Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2010
• Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2009
• Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors
  The Oncologist, 2007
• Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer
  Cancer Research, 2007
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker
  Journal of Clinical Oncology, 2006
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
  Cancer Research, 2004
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies
  Journal of Clinical Oncology, 2003
• Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
  Proceedings of the National Academy of Sciences, 2003
• Anti-angiogenic agents
  European Journal of Cancer, 2000